Nicole Rusaw-George
Finanzdirektor/CFO bei LIMINAL BIOSCIENCES INC.
Aktive Positionen von Nicole Rusaw-George
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LIMINAL BIOSCIENCES INC. | Finanzdirektor/CFO | 02.03.2022 | - |
Karriereverlauf von Nicole Rusaw-George
Ehemalige bekannte Positionen von Nicole Rusaw-George
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
COPLAND ROAD CAPITAL CORPORATION | Finanzdirektor/CFO | 01.10.2019 | 09.06.2022 |
IONIC BRANDS CORP. | Finanzdirektor/CFO | 01.06.2021 | 13.12.2021 |
NUVO PHARMACEUTICALS INC. | Finanzdirektor/CFO | 01.08.2017 | - |
NEUPATH HEALTH INC. | Direktor/Vorstandsmitglied | 01.04.2019 | - |
Finanzdirektor/CFO | 01.04.2019 | - | |
Unternehmenssekretär | - | - | |
TRANSITION THERAPEUTICS INC | Finanzdirektor/CFO | 13.12.2011 | - |
Corporate Officer/Principal | 04.07.2008 | 13.12.2011 |
Ausbildung von Nicole Rusaw-George
Brock University | Undergraduate Degree |
Statistik
International
Kanada | 7 |
Vereinigte Staaten | 2 |
Operativ
Director of Finance/CFO | 6 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
COPLAND ROAD CAPITAL CORPORATION | Process Industries |
IONIC BRANDS CORP. | Producer Manufacturing |
LIMINAL BIOSCIENCES INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Transition Therapeutics, Inc.
Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
Nuvo Pharmaceuticals, Inc.
Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Klinik Health Ventures Corp.
Klinik Health Ventures Corp. Financial ConglomeratesFinance Klinik Health Ventures Corp. operates as a capital pool company. The company was founded on April 17, 2019 and is headquartered in Toronto, Canada. | Finance |
- Börse
- Insiders
- Nicole Rusaw-George
- Erfahrung